Targeted Therapy for the Management of Oral Potentially Malignant Disorders: A Systematic Review.

IF 2.9 3区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE Oral diseases Pub Date : 2025-03-06 DOI:10.1111/odi.15307

Lauren Frenzel Schuch, Fábio Muradás Girardi, Laura Borges Kirschnick, Aline Lauda Freitas Chaves, Luiz Paulo Kowalski, Ronell Bologna-Molina, William Nassib William Junior, Manoela Domingues Martins, Alan Roger Santos-Silva

{"title":"Targeted Therapy for the Management of Oral Potentially Malignant Disorders: A Systematic Review.","authors":"Lauren Frenzel Schuch, Fábio Muradás Girardi, Laura Borges Kirschnick, Aline Lauda Freitas Chaves, Luiz Paulo Kowalski, Ronell Bologna-Molina, William Nassib William Junior, Manoela Domingues Martins, Alan Roger Santos-Silva","doi":"10.1111/odi.15307","DOIUrl":null,"url":null,"abstract":"Objective: This study aimed to integrate the available data published in the literature to identify and elucidate the impact of targeted therapy for oral potentially malignant disorders (OPMDs).Material and methods: This systematic review was conducted according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 statement. An electronic search across five databases with no publication date restriction was conducted in January 2023 and subsequently updated in January 2024. Eligibility criteria included studies focusing on targeted therapies. Interventions that either did not align with the specific definition of targeted therapy or failed to meet the criteria for precision-based treatment approaches were excluded from this review.Results: Six clinical trials were identified, all conducted in the United States. The sample size ranged from 12 to 150 subjects. Celecoxib, erlotinib, cetuximab, metformin, and nivolumab were employed as targeted systemic therapies at varying doses. Some patients experienced disease progression with no statistically significant differences in histological improvement rates or size increases. Certain studies reported treatment-related toxicity.Conclusion: The findings of this review do not support the use of targeted therapy in managing OPMDs, highlighting the need for additional clinical trials to further evaluate their efficacy.","PeriodicalId":19615,"journal":{"name":"Oral diseases","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/odi.15307","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study aimed to integrate the available data published in the literature to identify and elucidate the impact of targeted therapy for oral potentially malignant disorders (OPMDs).

Material and methods: This systematic review was conducted according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 statement. An electronic search across five databases with no publication date restriction was conducted in January 2023 and subsequently updated in January 2024. Eligibility criteria included studies focusing on targeted therapies. Interventions that either did not align with the specific definition of targeted therapy or failed to meet the criteria for precision-based treatment approaches were excluded from this review.

Results: Six clinical trials were identified, all conducted in the United States. The sample size ranged from 12 to 150 subjects. Celecoxib, erlotinib, cetuximab, metformin, and nivolumab were employed as targeted systemic therapies at varying doses. Some patients experienced disease progression with no statistically significant differences in histological improvement rates or size increases. Certain studies reported treatment-related toxicity.

Conclusion: The findings of this review do not support the use of targeted therapy in managing OPMDs, highlighting the need for additional clinical trials to further evaluate their efficacy.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Oral diseases 医学-牙科与口腔外科

CiteScore

7.60

自引率

5.30%

发文量

325

审稿时长

4-8 weeks

期刊介绍： Oral Diseases is a multidisciplinary and international journal with a focus on head and neck disorders, edited by leaders in the field, Professor Giovanni Lodi (Editor-in-Chief, Milan, Italy), Professor Stefano Petti (Deputy Editor, Rome, Italy) and Associate Professor Gulshan Sunavala-Dossabhoy (Deputy Editor, Shreveport, LA, USA). The journal is pre-eminent in oral medicine. Oral Diseases specifically strives to link often-isolated areas of dentistry and medicine through broad-based scholarship that includes well-designed and controlled clinical research, analytical epidemiology, and the translation of basic science in pre-clinical studies. The journal typically publishes articles relevant to many related medical specialties including especially dermatology, gastroenterology, hematology, immunology, infectious diseases, neuropsychiatry, oncology and otolaryngology. The essential requirement is that all submitted research is hypothesis-driven, with significant positive and negative results both welcomed. Equal publication emphasis is placed on etiology, pathogenesis, diagnosis, prevention and treatment.